ADXN Pengajuan SEC - Addex Therapeutics Ltd - Depositary Receipt (Common Stock)- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1574232

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Addex Therapeutics Ltd - Depositary Receipt (Common Stock)

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

June 30, 2025	EX-99.1	Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders EXHIBIT 99.1 Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announce
June 30, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39179 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executiv
June 25, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39179 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executiv
June 25, 2025	EX-99.1	Addex Shareholders Approve All Resolutions at Annual General Meeting EdgarFiling EXHIBIT 99.1 Addex Shareholders Approve All Resolutions at Annual General Meeting Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large major
June 20, 2025	EX-99.1	ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024 2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month periods ended March 31, 2025 and 202
June 20, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2025 Commission File Number: 001-39179 Addex Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2025 Commission File Number: 001-39179 Addex Therapeutics Ltd (Exact Name of Registrant as Specified in Its Charter) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive offices)
June 20, 2025	EX-99.3	Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update Exhibit 99.3 PRESS RELEASE Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update · Strong cash position of CHF2.8 million at end of Q1 2025 · GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models · Regained rights to our phase 2 mGlu2 PAM asset, ADX71149 · Indivior advanced GABAB PAM Substance use disorders program successfully t
June 20, 2025	EX-99.2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a clinical-stage pharmaceutical company focused on the development of a portfolio of novel orally available small molecule drug candidates. Our business comprises of a pipeline of proprietary clinical and preclinical stage drug candidates that are being developed by our partners and i
June 6, 2025	EX-99.1	Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models EdgarFiling EXHIBIT 99.1 Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurolo
June 6, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39179 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executiv
May 15, 2025	EX-4.22	SALE AGENCY AGREEMENT ADDEX THERAPEUTICS KEPLER CHEUVREUX Exhibit 4.22 SALE AGENCY AGREEMENT BETWEEN ADDEX THERAPEUTICS And KEPLER CHEUVREUX 116 Paris Kepler Cheuvreux Siège social : 112 avenue Kléber 75116 Paris France http://www.keplercheuvreux.com/ Tél : +33 1 53 65 35 00 Société anonyme à Directoire et Conseil de surveillance au capital de 56.371.350 € - RCS Paris B 413 064 841, APE 652 E - Identification TVA FR 38413064841, Entreprise d’investisseme
May 15, 2025	EX-12.1	Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 CERTIFICATIONS I, Tim Dyer, certify that: 1.I have reviewed this annual report on Form 20-F of Addex Therapeutics Ltd (the “Company”); 2.Based on my knowledge, this report does not contain any untrue sta
May 15, 2025	EX-1.1	Article 1 Exhibit 1.1 Articles of Association of Addex Therapeutics Ltd I.Corporate Name, Registered Office, Duration, Purpose Article 1 Corporate Name, Registered Office, Duration Under the name Addex Therapeutics Ltd (Addex Therapeutics SA) (the "Company") exists a corporation which is subject to these Articles of Association and the provisions of Chapter 26 of the Swiss Code of Obligations (CO). The regi
May 15, 2025	EX-13.1	Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 CERTIFICATIONS In connection with the Annual Report of Addex Therapeutics Ltd (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Repo
May 15, 2025	EX-11.1	CORPORATE POLICY Exhibit 11.1 CORPORATE POLICY Document Name: Securities Trading Policy Revision: 01 Reason for Revision: For SEC compliance Author: Homburger AG - Guy Deillon, MLaw, LL.M. Cooley LLC – Joshua Kaufman Esq Adopted: 28th Jan 2020 Approved by: Vincent Lawton Tim Dyer Chairman of the Board Secretary to the Board 1 \| 11 CORPORATE POLICY Document Name: Securities Trading Policy Revision: 01 Adopted: 28th
May 15, 2025	EX-12.2	Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 CERTIFICATIONS I, Lénaïc Teyssédou, certify that: 1.I have reviewed this annual report on Form 20-F of Addex Therapeutics Ltd (the “Company”); 2.Based on my knowledge, this report does not contain any un
May 15, 2025	EX-13.2	Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Addex Therapeutics Ltd (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lénaïc
May 15, 2025	EX-2.4	DESCRIPTION OF SECURITIES Exhibit 2.4 DESCRIPTION OF SECURITIES The following section describes our issued share capital as of December 31, 2024, summarizes the material provisions of our Articles and highlights certain differences in corporate law in Switzerland and the United States. Capital structure There were 2,274 shareholders registered in the share register on December 31, 2024. The distribution of shareholdings is
May 15, 2025	EX-15.1	Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm Addex Therapeutics Ltd Geneva, Switzerland We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-255089) and Form S-8 (No. 333-255124) of Addex Therapeutics Ltd (the Company) of our report dated May 15, 2025, relating to the consolidated financial statements appearing in the Comp
May 15, 2025	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
May 12, 2025	EX-99.1	Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies EdgarFiling EXHIBIT 99.1 Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological
May 12, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39179 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive
April 30, 2025	EX-99.1	Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery EXHIBIT 99.1 Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteri
April 30, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-3917 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executi
April 30, 2025	NT 20-F	Read Instruction (on back page) Before Preparing Form. Please Print or Type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 SEC FILE NUMBER CUSIP NUMBER NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K x Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2024 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Fo
April 25, 2025	EX-99.2	Addex Reports Full Year 2024 Financial Results and Provides Corporate Update EdgarFiling EXHIBIT 99.2 Addex Reports Full Year 2024 Financial Results and Provides Corporate Update Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolio Indivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance use disorders Addex selected independent GABAB PAM drug candidate for developm
April 25, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-3917 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executi
April 17, 2025	EX-99.1	Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149 EdgarFiling EXHIBIT 99.1 Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 17, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that following the previously a
April 17, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-3917 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executi
November 22, 2024	EX-99.3	Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.3 PRESS RELEASE Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update · Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 22, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company
November 22, 2024	EX-99.1	ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 2 Unaudited Interim Condensed Consolidated Statements of Profit or Loss for the three-month and nine-month periods ended Septemb
November 22, 2024	EX-99.2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a clinical-stage pharmaceutical company focused on the development of a portfolio of novel orally available small molecule drug candidates. Our business comprises of a pipeline of proprietary clinical and preclinical stage drug candidates that are being developed by our partners and i
November 22, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 2024 Commission File Number: 001-39179 Addex Therap UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Exact Name of Registrant as Specified in Its Charter) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive offi
November 12, 2024	EX-99.1	Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024 Nine-month Results Remain On Track for Net Profit EXHIBIT 99.1 Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024 Nine-month Results Remain On Track for Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulator
November 12, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal exec
September 30, 2024	EX-99.3	Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update Exhibit 99.3 PRESS RELEASE Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update · Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophrenia · Indivior selected GABA B PAM drug candidate for development in substance use disorders · Addex selected independent GABAB PAM drug candidate for development
September 30, 2024	EX-99.2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a clinical-stage pharmaceutical company focused on the development of a portfolio of novel orally available small molecule drug candidates. Our business comprises of a pipeline of proprietary clinical and preclinical stage drug candidates that are being developed by our partners and i
September 30, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 2024 Commission File Number: 001-39179 Addex Thera UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Exact Name of Registrant as Specified in Its Charter) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive off
September 30, 2024	EX-99.1	ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 2 Unaudited Interim Condensed Consolidated Statements of Profit or Loss for the three-month and six-month periods ended June 30, 2024
September 19, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal exe
September 19, 2024	EX-99.1	Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit EXHIBIT 99.1 Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced t
August 27, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-391 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal execut
August 27, 2024	EX-99.1	Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration EXHIBIT 99.1 Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, and I
August 14, 2024	SC 13D/A	ADXN / Addex Therapeutics Ltd - Depositary Receipt (Common Stock) / Growth Equity Opportunities Fund IV, LLC - GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D/A(#7E) Activist Investment SC 13D/A 1 geoiv-addex18864.htm GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D/A(#7E) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Addex Therapeutics Ltd. (Name of Issuer) Shares, nominal value CHF 0.01 per share (represented by American Depositary Shares) (Title of Class o
August 5, 2024	SC 13D/A	ADXN / Addex Therapeutics Ltd - Depositary Receipt (Common Stock) / Growth Equity Opportunities Fund IV, LLC - GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D/A(#6) Activist Investment SC 13D/A 1 geoiv-addex18859.htm GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D/A(#6) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Addex Therapeutics Ltd. (Name of Issuer) Shares, nominal value CHF 0.01 per share (represented by American Depositary Shares) (Title of Class of
July 22, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39179 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executiv
July 22, 2024	EX-99.1	Addex’s Partner Discontinues ADX71149 development in Epilepsy EXHIBIT 99.1 Addex’s Partner Discontinues ADX71149 development in Epilepsy Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its partner Janssen Pharmaceut
July 15, 2024	EX-99.1	Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS) EXHIBIT 99.1 Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS) Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neu
July 15, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39179 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executiv
July 1, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39179 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executiv
July 1, 2024	EX-99.1	Addex Shareholders Approve All Resolutions at Annual General Meeting EXHIBIT 99.1 Addex Shareholders Approve All Resolutions at Annual General Meeting Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all prop
June 6, 2024	EX-99.1	ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month periods ended March 31, 2023 and 202
June 6, 2024	EX-99.2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a clinical-stage pharmaceutical company focused on the development of a portfolio of novel orally available small molecule drug candidates. Our business comprises of a pipeline of proprietary clinical and preclinical stage drug candidates that are being developed by our partners and i
June 6, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2024 Commission File Number: 001-39179 Addex Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Exact Name of Registrant as Specified in Its Charter) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive offices)
June 6, 2024	EX-99.3	Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update Exhibit 99.3 PRESS RELEASE Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update ● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a po
June 5, 2024	EX-99.1	Addex Convenes Annual General Meeting 2024 EdgarFiling EXHIBIT 99.1 Addex Convenes Annual General Meeting 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2024 Annual General Meeting
June 5, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39179 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executiv
April 29, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-3917 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executi
April 29, 2024	EX-99.1	Addex Provides Update on ADX71149 Phase 2 Epilepsy Study EXHIBIT 99.1 Addex Provides Update on ADX71149 Phase 2 Epilepsy Study Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced top-line data from a Phase 2 epilepsy s
April 24, 2024	424B3	Up to 465,081 American Depositary Shares Representing 55,809,720 Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No.333-271611 PROSPECTUS Up to 465,081 American Depositary Shares Representing 55,809,720 Shares This prospectus relates to the resale by the selling shareholder identified herein of up to 465,081 ADSs representing 55,809,720 of our ordinary shares, consisting of Warrants with an exercise price of USD 20.00 per ADS and expiring, on
April 18, 2024	EX-13.1	Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 CERTIFICATIONS In connection with the Annual Report of Addex Therapeutics Ltd (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Repo
April 18, 2024	EX-13.2	Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Addex Therapeutics Ltd (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lénaïc
April 18, 2024	POS AM	As filed with the Securities and Exchange Commission on April 18, 2024. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 18, 2024.
April 18, 2024	EX-15.1	Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-255089) and S- 8 (No. 333- 255124) of our report dated April 18, 2024, relating to the consolidated financial statements appearing in the Company’s Annual Report on Form 20-F for the year ended December 31, 2023. BDO AG /s/ Ch
April 18, 2024	EX-4.21	[Signatures on next page] Exhibit 4.21 Service agreement [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) CUSTOMARILY AND ACTUALLY TREATED BY THE REGISTRANT AS PRIVATE OR CONFIDENTIAL. Service Agreement dated as of April 2, 2024 between Neurosterix Pharma Sàrl (Neurosterix) Chemin des Mines 9 1202 Geneva Switzerland and Addex Ph
April 18, 2024	EX-12.2	Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 CERTIFICATIONS I, Lénaïc Teyssédou, certify that: 1.I have reviewed this annual report on Form 20-F of Addex Therapeutics Ltd (the “Company”); 2.Based on my knowledge, this report does not contain any un
April 18, 2024	EX-99.1	Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update EdgarFiling EXHIBIT 99.1 Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024 Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing cash
April 18, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-3917 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executi
April 18, 2024	EX-97.1	ADDEX THERAPEUTICS LTD INCENTIVE COMPENSATION RECOUPMENT POLICY Exhibit 97.1 ADDEX THERAPEUTICS LTD INCENTIVE COMPENSATION RECOUPMENT POLICY 1.INTRODUCTION The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Addex Therapeutics Ltd, a stock corporation organized under the laws of Switzerland (the “Company”), has determined that it is in the best interests of the Company and its shareholders to adopt this Incentiv
April 18, 2024	EX-12.1	Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 CERTIFICATIONS I, Tim Dyer, certify that: 1.I have reviewed this annual report on Form 20-F of Addex Therapeutics Ltd (the “Company”); 2.Based on my knowledge, this report does not contain any untrue sta
April 18, 2024	EX-2.4	DESCRIPTION OF SHARE CAPITAL Exhibit 2.4 DESCRIPTION OF SHARE CAPITAL The following section describes our issued share capital as of February 29, 2024, summarizes the material provisions of our Articles and highlights certain differences in corporate law in Switzerland and the United States. Capital structure There were 2,450 shareholders registered in the share register on February 29, 2024. The distribution of shareholdings
April 18, 2024	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
April 18, 2024	EX-1.1	Article 1 Exhibit 1.1 Articles of Association of Addex Therapeutics Ltd I.Corporate Name, Registered Office, Duration, Purpose Article 1 Corporate Name, Registered Office, Duration Under the name Addex Therapeutics Ltd (Addex Therapeutics SA) (the "Company") exists a corporation which is subject to these Articles of Association and the provisions of Chapter 26 of the Swiss Code of Obligations (CO). The regi
April 3, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-3917 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executi
April 3, 2024	EX-99.1	Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders Addex receives CHF5M and 20% share of Neurosterix Perceptive Advisors leads $63M investment into Neuros EdgarFiling EXHIBIT 99.1 Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders Addex receives CHF5M and 20% share of Neurosterix Perceptive Advisors leads $63M investment into Neurosterix Addex contributes portfolio of preclinical neuroscience assets and allosteric modulator small molecule discovery techno
January 30, 2024	424B5	Up to $2,150,000 American Depositary Shares Representing Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-255089 PROSPECTUS SUPPLEMENT (To prospectus dated April 13, 2021) Up to $2,150,000 American Depositary Shares Representing Shares We have entered into an At The Market Offering Agreement, or the sales agreement, dated January 30, 2024, with H.C. Wainwright & Co., LLC, or H.C. Wainwright, relating to offer and sale of our Ame
January 30, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal execu
January 30, 2024	EX-1.1	AT THE MARKET OFFERING AGREEMENT Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT January 30, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor New York, New York 10022 Ladies and Gentlemen: Addex Therapeutics Ltd, a stock corporation (Aktiengesellschaft) incorporated under the laws of Switzerland (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1.
December 21, 2023	EX-99.1	ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements 2 Unaudited Interim Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022 2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month and six-month periods ended June 30
December 21, 2023	6-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: December 2023 Commission F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: December 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant’s name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address
December 20, 2023	EX-99.1	Addex Shareholders Approve All Resolutions at Extraordinary General Meeting EXHIBIT 99.1 Addex Shareholders Approve All Resolutions at Extraordinary General Meeting Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 20, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the Company”), announced today that its shareholders approved, wit
December 20, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal exec
December 14, 2023	EX-99.1	Addex Creates Treasury Shares EXHIBIT 99.1 Addex Creates Treasury Shares Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 14, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the Company”), announced today that 15,300,000 new registered shares at a nominal value of CHF 0.01 have been is
December 14, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal exec
December 8, 2023	SC 13D/A	CH:ADXN / Addex Therapeutics Ltd / Growth Equity Opportunities Fund IV, LLC - GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D/A(#5) Activist Investment SC 13D/A 1 geoiv-addex18778.htm GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D/A(#5) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Addex Therapeutics Ltd. (Name of Issuer) Shares, nominal value CHF .01 per share (represented by American Depositary Shares) (Title of Class of
November 30, 2023	424B3	Up to 516,081 American Depositary Shares Representing 61,929,720 Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-271611 PROSPECTUS Up to 516,081 American Depositary Shares Representing 61,929,720 Shares This prospectus relates to the resale, by the selling shareholder identified in this prospectus, of up to 516,081 American Depositary Shares, or ADSs consisting of (i) warrants to purchase up to an aggregate of 55,809,720 shares, repres
November 29, 2023	EX-99.1	ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022 2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month and nine-month periods ended Sep
November 29, 2023	POS AM	As filed with the Securities and Exchange Commission on November 29, 2023. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 29, 2023.
November 29, 2023	EX-99.3	Addex Reports Q3 2023 Financial Results and Provides Corporate Update Exhibit 99.3 PRESS RELEASE Addex Reports Q3 2023 Financial Results and Provides Corporate Update · ADX71149 Phase 2 epilepsy clinical study completes recruitment of patients, with top line results expected in Q2 2024 · mGlu2 NAM cognition program receives a €4 million Eurostars grant · CHF 4.8M ($5.2M) of cash and cash equivalents at September 30, 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Ge
November 29, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 2023 Commission File Number: 001-39179 Addex Therap UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Exact Name of Registrant as Specified in Its Charter) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive offi
November 29, 2023	EX-99.2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators. Allosteric modulators target a specific receptor or protein and alter the effect of the body’s o
November 29, 2023	SC 13D/A	CH:ADXN / Addex Therapeutics Ltd / Dyer Timothy Mark - SC 13D/A Activist Investment SC 13D/A 1 tm2331756d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Addex Therapeutics Ltd (Name of Issuer) American Depositary Shares, each representing 120 ordinary shares Ordinary shares (Title of Class of Securities) 00654J206** (CUSIP Number) Timothy Mark Dyer c/o Addex Ther
November 28, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal exec
November 28, 2023	EX-99.1	Addex Convenes Extraordinary General Meeting EXHIBIT 99.1 Addex Convenes Extraordinary General Meeting Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 28, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that an Extraordinary General Meeting is convened and will take place on Tuesday D
November 14, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal exec
November 14, 2023	EX-99.1	Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients EXHIBIT 99.1 Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients Top line results expected in Q2 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 14, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the last patient ha
November 8, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal exec
November 8, 2023	EX-99.1	Addex Regains Nasdaq Listing Compliance EdgarFiling EXHIBIT 99.1 Addex Regains Nasdaq Listing Compliance Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 8, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced it had received written notification from The Nasdaq Stock Market LLC (Nasdaq) tha
October 23, 2023	424B3	Up to 581,981 American Depositary Shares Representing 69,837,720 Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) File No. 333-271611 PROSPECTUS Up to 581,981 American Depositary Shares Representing 69,837,720 Shares This prospectus relating to the resale, by the selling shareholder identified in this prospectus of American Depositary Shares, or ADSs, has been filed following the change in our ADS ratio from one ADS to six ordinary shares to the new ADS rat
October 20, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal execu
October 20, 2023	EX-99.1	Addex Completes ADS Ratio Change EXHIBIT 99.1 Addex Completes ADS Ratio Change Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 20, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the Company’s previously disclosed change to its American Depositary Shares (“ADSs”) to ordinary
October 6, 2023	F-6 POS	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-6 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS Addex Therapeutics Ltd (Ex As filed with the Securities and Exchange Commission on October 6, 2023 Registration No.
October 6, 2023	EX-99.1	Addex Announces Plan to Implement ADS Ratio Change EXHIBIT 99.1 Addex Announces Plan to Implement ADS Ratio Change Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its
October 6, 2023	EX-99.(A)(II)	DEPOSIT AGREEMENT by and among ADDEX THERAPEUTICS LTD CITIBANK, N.A., as Depositary, THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of January 29, 2020 TABLE OF CONTENTS Exhibit (a)(ii) EXECUTION VERSION DEPOSIT AGREEMENT by and among ADDEX THERAPEUTICS LTD and CITIBANK, N.
October 6, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal execu
October 6, 2023	EX-99.(A)(I)	ADDEX THERAPEUTICS LTD CITIBANK, N.A., as Depositary, THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES OUTSTANDING UNDER THE TERMS OF THE DEPOSIT AGREEMENT, DATED AS OF January 29, 2020 Amendment No. 1 the Deposit Agreement Dated as of Exhibit (a)(i) ADDEX THERAPEUTICS LTD and CITIBANK, N.A., as Depositary, ands THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES OUTSTANDING UNDER THE TERMS OF THE DEPOSIT AGREEMENT, DATED AS OF January 29, 2020 Amendment No. 1 to the Deposit Agreement Dated as of [l], 2023 Table of Contents Page ARTICLE I DEFINITIONS 2 Section 1.1 Definitions. 2 Section 1.2 Effective Date 2 ARTICLE I
September 20, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal exe
September 20, 2023	EX-99.1	Addex mGlu2 NAM Cognition Program Receives €4 Million Grant EXHIBIT 99.1 Addex mGlu2 NAM Cognition Program Receives €4 Million Grant Addex led consortium wins Eurostars grant to deliver clinical candidates to treat mild neurocognitive disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 20, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug dis
September 5, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal exe
September 5, 2023	EX-99.1	Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain EdgarFiling EXHIBIT 99.1 Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain Landmark study shows mGlu5 receptor negative allosteric modulators (NAMs) restore lost neurological functions First time mGlu5 linked to post-stroke functional recovery Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 4, 2023 - Addex Therapeutics (SIX and
September 5, 2023	EX-99.1	Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024 EdgarFiling EXHIBIT 99.1 Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024 Cohort 1 is completed, and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today anno
September 5, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal exe
August 11, 2023	424B3	Up to 12,156,620 American Depositary Shares Representing 72,939,720 Shares TABLE OF CONTENTS Filed pursuant to Rule 424(b)(3) File No. 333-271611 PROSPECTUS Up to 12,156,620 American Depositary Shares Representing 72,939,720 Shares This prospectus relates to the resale, by the selling shareholder identified in this prospectus, of up to 12,156,620 American Depositary Shares, or ADSs, consisting of (i) warrants to purchase up to an aggregate of 31,578,948 shares, repres
August 10, 2023	EX-3.1	Article 1 Exhibit 3.1 Articles of Association of Addex Therapeutics Ltd I. Corporate Name, Registered Office, Duration, Purpose Article 1 Corporate Name, Registered Office, Duration Under the name Addex Therapeutics Ltd (Addex Therapeutics SA) (the "Company") exists a corporation which is subject to these Articles of Association and the provisions of Chapter 26 of the Swiss Code of Obligations (CO). The reg
August 10, 2023	EX-99.1	ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022 2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month and six-month periods ended June 30,
August 10, 2023	EX-99.2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators. Allosteric modulators target a specific receptor or protein and alter the effect of the body’s o
August 10, 2023	POS AM	As filed with the Securities and Exchange Commission on August 10, 2023. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 10, 2023.
August 10, 2023	EX-99.3	Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update Exhibit 99.3 Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update · ADX71149 Phase 2 epilepsy clinical study Cohort 2 continues recruiting following the Independent Interim Review Committee (IRC) recommendation · Indivior GABAB PAM collaboration extended to June 2024 with CHF 2.7 million of committed research funding · CHF 7.2M ($8.0M) of cash and cash eq
August 10, 2023	EX-10.20	AMENDMENT No. 5 Exhibit 10.20 Certain confidential portions of this exhibit have been omitted and replaced with “[***].” Such identified information has been excluded from this exhibit because it (i) is not material and (ii) is the type of information that the registrant treats as private or confidential. AMENDMENT No. 5 Whereas, Addex Pharma SA (“Addex”) and Indivior UK Limited (Co. No. 7183451) (“Indivior”) (ea
August 10, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2023 Commission File Number: 001-39179 Addex Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Exact Name of Registrant as Specified in Its Charter) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive office
August 10, 2023	EX-10.19	SALE AGENCY AGREEMENT ADDEX THERAPEUTICS KEPLER CHEUVREUX Exhibit 10.19 SALE AGENCY AGREEMENT BETWEEN ADDEX THERAPEUTICS And KEPLER CHEUVREUX Kepler Cheuvreux http://www.keplercheuvreux.com/ Tél : +33 1 53 65 35 00 Société anonyme à Directoire et Conseil de surveillance au capital de 56.371.350 € - RCS Paris B 413 064 841, APE 652 E - Identification TVA FR 38413064841, Entreprise d’investissement régie par la loi n° 96-597 du 02.07.96 Siège social : 112
August 3, 2023	EX-99.1	Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration EXHIBIT 99.1 Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration Discovery collaboration on track to deliver clinical candidates for IND enabling studies in 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 3, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clini
August 3, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-391 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal execut
July 24, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39179 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executiv
July 24, 2023	EX-99.1	Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder EdgarFiling EXHIBIT 99.1 Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder Data published in Neuropharmacology shows mGlu2 PAMs attenuate oxycodone use and potential as a novel treatment for opioid use disorder Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 24, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering a
June 15, 2023	EX-99.1	Addex Increases Issued Share Capital to Create Treasury Shares EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Addex Increases Issued Share Capital to Create Treasury Shares Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 15, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the Company”), announced today that it has incre
June 15, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39179 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executiv
June 8, 2023	S-8	As filed with the Securities and Exchange Commission on June 8, 2023 As filed with the Securities and Exchange Commission on June 8, 2023 Registration No.
June 8, 2023	EX-FILING FEES	Calculation of Filing Fee Tables Form S-8 (Form Type) Addex Therapeutics Ltd (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Addex Therapeutics Ltd (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered (2) Proposed Maximum Offering Price Per Share (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, with a nominal value of CHF 0.
June 2, 2023	424B3	Up to 13,231,445 American Depositary Shares Representing 79,388,670 Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) File No. 333-271611 PROSPECTUS Up to 13,231,445 American Depositary Shares Representing 79,388,670 Shares This prospectus relates to the resale, by the selling shareholder identified in this prospectus, of up to 13,231,445 American Depositary Shares, or ADSs, consisting of (i) warrants to purchase up to an aggregate of 31,578,948 shares, represe
June 1, 2023	EX-3.1	Article 1 Exhibit 3.1 Articles of Association of Addex Therapeutics Ltd I. Corporate Name, Registered Office, Duration, Purpose Article 1 Corporate Name, Registered Office, Duration Under the name Addex Therapeutics Ltd (Addex Therapeutics SA) (the "Company") exists a corporation which is subject to these Articles of Association and the provisions of Chapter 26 of the Swiss Code of Obligations (CO). The reg
June 1, 2023	CORRESP	Addex Therapeutics Ltd Chemin des Mines 9, CH-1202 Geneva, Switzerland Addex Therapeutics Ltd Chemin des Mines 9, CH-1202 Geneva, Switzerland June 1, 2023 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
June 1, 2023	EX-99.1	Addex Shareholders Approve All Resolutions at Annual General Meeting EdgarFiling EXHIBIT 99.1 Addex Shareholders Approve All Resolutions at Annual General Meeting Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 1, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the Company”), announced today that its shareholders approved, wit
June 1, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39179 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executiv
June 1, 2023	F-1/A	As filed with the Securities and Exchange Commission on June 1, 2023. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 1, 2023.
May 18, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39179 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive
May 18, 2023	EX-99.1	Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency EdgarFiling EXHIBIT 99.1 Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 18, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (the Company), announced today that it had received written not
May 12, 2023	CORRESP	Addex Therapeutics Ltd Chemin des Mines 9, CH-1202 Geneva, Switzerland Addex Therapeutics Ltd Chemin des Mines 9, CH-1202 Geneva, Switzerland May 12, 2023 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
May 11, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2023 Commission File Number: 001-39179 Addex Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Exact Name of Registrant as Specified in Its Charter) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive offices)
May 11, 2023	F-1/A	As filed with the Securities and Exchange Commission on May 11, 2023. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 11, 2023.
May 11, 2023	EX-99.2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.2 3 tm2315254d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators. Allosteric modulators target a specific receptor or
May 11, 2023	CORRESP	Addex Therapeutics Ltd Chemin des Mines 9, CH-1202 Geneva, Switzerland Addex Therapeutics Ltd Chemin des Mines 9, CH-1202 Geneva, Switzerland May 11, 2023 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
May 11, 2023	EX-99.3	Addex Reports Q1 2023 Financial Results and Provides Corporate Update Exhibit 99.3 Addex Reports Q1 2023 Financial Results and Provides Corporate Update · ADX71149 Phase 2 epilepsy clinical study’s independent interim review committee (“IRC”) recommends continuing study · CHF 5.6M ($ 6.1M) of cash and cash equivalents at March 31, 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 11, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a cl
May 11, 2023	EX-99.1	ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022 2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month periods ended March 31, 2023 and 202
May 10, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39179 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive
May 10, 2023	EX-99.1	Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study EXHIBIT 99.1 Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study Cohort 1 progressing through Part 2 Cohort 2 recruiting patients Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-bas
May 5, 2023	EX-99.1	Addex Convenes Annual General Meeting 2023 EdgarFiling EXHIBIT 99.1 Addex Convenes Annual General Meeting 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 5, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its Annual General Meeting will take place on Wednesday May 31, 2023, at
May 5, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39179 6-K 1 f6k050523.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (A
May 3, 2023	F-1	As filed with the Securities and Exchange Commission on May 3, 2023. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 3, 2023.
May 3, 2023	EX-FILING FEES	CALCULATION OF REGISTRATION FEE FORM F-1 (Form Type) ADDEX THERAPEUTICS ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 CALCULATION OF REGISTRATION FEE FORM F-1 (Form Type) ADDEX THERAPEUTICS ltd.
April 10, 2023	SC 13D/A	CH:ADXN / Addex Therapeutics Ltd / Growth Equity Opportunities Fund IV, LLC - GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D/A(#4) Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Addex Therapeutics Ltd. (Name of Issuer) Shares, nominal value CHF .01 per share (represented by American Depositary Shares) (Title of Class of Securities) 00654J107 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greensp
April 5, 2023	SC 13D/A	CH:ADXN / Addex Therapeutics Ltd / Dyer Timothy Mark - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Addex Therapeutics Ltd (Name of Issuer) American Depositary Shares, each representing 6 ordinary shares Ordinary shares (Title of Class of Securities) 00654J107** (CUSIP Number) Timothy Mark Dyer c/o Addex Therapeutics Ltd Chemin des Mines 9, CH- 1202 Ge
April 4, 2023	EX-4.1	WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES ADDEX THERAPEUTICS LTD Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
April 4, 2023	EX-4.3	AMENDED AND RESTATED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES ADDEX THERAPEUTICS LTD Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
April 4, 2023	EX-10.2	Annex A - Form of Amended 2021 Warrant Annex B - Form of Amended 2022 Warrant Exhibit 10.2 April 3, 2023 Armistice Capital Master Fund Ltd. 510 Madison Avenue, 7th Floor New York, NY 10022 Re: Reprice Offer of Ordinary Warrants To Whom It May Concern: Addex Therapeutics Ltd (the “Company”) previously issued and delivered to you (“Holder” or “you”) (i) a warrant (the “Original 2021 Warrant”) exercisable into 9,230,772 ordinary shares of the Company, nominal value CHF 0.01 pe
April 4, 2023	EX-4.4	AMENDED AND RESTATED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES ADDEX THERAPEUTICS LTD Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
April 4, 2023	424B5	7,999,998 Shares (in the form of 1,333,333 American Depositary Shares) CHF 0.145 per Share $0.95 per American Depositary Share TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-255089 PROSPECTUS SUPPLEMENT (to Prospectus dated April 13, 2021) 7,999,998 Shares (in the form of 1,333,333 American Depositary Shares) CHF 0.145 per Share $0.95 per American Depositary Share We are offering 7,999,998 shares in the form of American Depositary Shares, or ADSs, in the United States to an institution
April 4, 2023	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 3, 2023, between Addex Therapeutics Ltd, a société anonyme organized under the laws of Switzerland (the “Company”), and the purchaser identified on the signature pages hereto (the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to
April 4, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of April 2023 Commission File Number: 001-3917 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of April 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant’s name into English) Chemin des Mines 9 CH-1202 Geneva, Switzerland (Address of principal executiv
April 4, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-3917 6-K 1 f6k040423.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland
April 4, 2023	EX-4.2	PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES ADDEX THERAPEUTICS LTD Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
April 4, 2023	EX-99.1	Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease EdgarFiling EXHIBIT 99.1 Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 4, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced data showin
April 3, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-3917 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executi
April 3, 2023	EX-99.1	Addex Raises $5.0 Million in Equity Financing EXHIBIT 99.1 Addex Raises $5.0 Million in Equity Financing Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 3, 2023 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with a leading institutional heal
March 31, 2023	SC 13D/A	CH:ADXN / Addex Therapeutics Ltd / Dyer Timothy Mark - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Addex Therapeutics Ltd (Name of Issuer) American Depositary Shares, each representing 6 ordinary shares Ordinary shares (Title of Class of Securities) 00654J107** (CUSIP Number) Timothy Mark Dyer c/o Addex Therapeutics Ltd Chemin des Mines 9, CH- 1202 Ge
March 30, 2023	EX-99.1	Addex Reports Full Year 2022 Financial Results and Provides Corporate Update EXHIBIT 99.1 Addex Reports Full Year 2022 Financial Results and Provides Corporate Update CHF 7.0M ($ 7.4M) of cash and cash equivalents at December 31, 2022 ADX71149 Phase 2 study in epilepsy cohort 1 completes part 1 – independent interim review committee (IRC) recommendation expected early Q2 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, March 30, 2023 - Addex Therapeutic
March 30, 2023	EX-4.15	Annex A Exhibit 4.15 Execution Version September 27, 2021 STRICTLY CONFIDENTIAL Addex Therapeutics Ltd Chemin des Mines 9, CH-1202 Geneva Switzerland Attn: Tim Dyer, Chief Executive Officer Dear Mr. Dyer: This letter agreement (this “Agreement”) constitutes the agreement between Addex Therapeutics Ltd (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusi
March 30, 2023	EX-13.2	Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Addex Therapeutics Ltd (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lénaïc
March 30, 2023	EX-12.1	Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 CERTIFICATIONS I, Tim Dyer, certify that: 1.I have reviewed this annual report on Form 20-F of Addex Therapeutics Ltd (the “Company”); 2.Based on my knowledge, this report does not contain any untrue sta
March 30, 2023	EX-1.1	Article 1 Exhibit 1.1 Articles of Association of Addex Therapeutics Ltd I.Corporate Name, Registered Office, Duration, Purpose Article 1 Corporate Name, Registered Office, Duration Under the name Addex Therapeutics Ltd (Addex Therapeutics SA) (the “Company”) exists a corporation which is subject to these Articles of Association and the provisions of Chapter 26 of the Swiss Code of Obligations (CO). The regi
March 30, 2023	EX-15.1	Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm Addex Therapeutics Ltd Geneva, Switzerland We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-255089) and S-8 (No. 333-255124) of our report dated March 30, 2023, relating to the consolidated financial statements of Addex Therapeutics Ltd, which is included in this Form 20-F.
March 30, 2023	EX-2.4	DESCRIPTION OF SHARE CAPITAL Exhibit 2.4 DESCRIPTION OF SHARE CAPITAL The following section describes our issued share capital as of March 17, 2023, summarizes the material provisions of our Articles of Association and highlights certain differences in corporate law in Switzerland and the United States. Capital structure There were 2,484 shareholders registered in the share register on March 17, 2023. The distribution of shar
March 30, 2023	EX-13.1	Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 CERTIFICATIONS In connection with the Annual Report of Addex Therapeutics Ltd (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Repo
March 30, 2023	EX-4.14	AMENDMENT No. 4 Exhibit 4.14 Certain confidential portions of this exhibit have been omitted and replaced with “[***].” Such identified information has been excluded from this exhibit because it (i) is not material and (ii) is the type of information that the registrant treats as private or confidential. AMENDMENT No. 4 Whereas, Addex Pharma SA (“Addex”) and Indivior UK Limited (Co. No. 7183451) (“Indivior”) (eac
March 30, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-3917 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executi
March 30, 2023	EX-4.5	ADDEX THERAPEUTICS LTD SHARE OPTION PLAN Exhibit 4.5 ADDEX THERAPEUTICS LTD SHARE OPTION PLAN 1 TABLE OF CONTENTS INTRODUCTION 3 General Information 3 THE PLAN 3 A. General Terms and Definitions 3 Article 1 Purpose 3 Article 2 Definitions 3 Article 3 Shares subject to the Plan 5 B. Administration 5 Article 4 Board of Directors 6 C. Grant of Options 6 Article 5 Eligibility and Conditions of Participation 6 Article 6 Procedure 6 Article 7
March 30, 2023	EX-12.2	Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 CERTIFICATIONS I, Lénaïc Teyssédou, certify that: 1.I have reviewed this annual report on Form 20-F of Addex Therapeutics Ltd (the “Company”); 2.Based on my knowledge, this report does not contain any un
March 30, 2023	20-F	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
February 16, 2023	SC 13G/A	CH:ADXN / Addex Therapeutics Ltd / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-adxn123122a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Addex Therapeutics Ltd (Name of Issuer) American Depositary Shares, each representing 6 ordinary shares, CHF 1.00 per share (Title of Class of Securities) 00654J107 (CUSIP Number) December 31, 2022 (Date of Event Whi
February 14, 2023	SC 13G/A	CH:ADXN / Addex Therapeutics Ltd / CAXTON CORP Passive Investment SC 13G/A 1 d993989613g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Addex Therapeutics Ltd (Name of Issuer) Shares, nominal value CHF 0.01 per share (represented by American Depositary Shares) (Title of Class of Securities) 00654J107 (CUSIP Number) December 31, 2022 (Date of Event Which Require
February 14, 2023	SC 13G/A	CH:ADXN / Addex Therapeutics Ltd / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-adxn123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Addex Therapeutics Ltd (Name of Issuer) Shares, nominal value CHF 1.00 per share (represented by American Depository Shares) (Title of Class of Securities) 00654J107 (CUSIP Number) December 31, 2022 (Date of Event Wh
February 9, 2023	EX-99.1	Addex Regains Nasdaq Listing Compliance EXHIBIT 99.1 Addex Regains Nasdaq Listing Compliance Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 9, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced notification from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with th
February 9, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal exec
February 6, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal exec
February 6, 2023	SC 13G/A	CH:ADXN / Addex Therapeutics Ltd / New Leaf Biopharma Opportunities I, L.P. - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 3) Addex Therapeutics Ltd. (Name of Issuer) Shares, nominal value CHF 1.00 per share (represented by American Depositary Shares) (Title of Class of Securities) 00654J
February 6, 2023	EX-99.1	Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1 EdgarFiling EXHIBIT 99.1 Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1 Data to be reviewed by independent interim review committee (IRC) to keep study blinded Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-b
January 19, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39 6-K 1 f6k011923.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerlan
January 19, 2023	EX-99.1	Addex Provides Corporate Update and Financial Guidance EXHIBIT 99.1 Addex Provides Corporate Update and Financial Guidance Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 19, 2023 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today provided a corporate update, including a review of its pipeline and financial guid
December 8, 2022	EX-99.1	Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration EXHIBIT 99.1 Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration Addex to receive USD 1 million in additional research funding Collaboration continues to advance through drug candidate selection phase Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 8, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN),
December 8, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal exec
November 28, 2022	SC 13D/A	CH:ADXN / Addex Therapeutics Ltd / Growth Equity Opportunities Fund IV, LLC - GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D/A3 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Addex Therapeutics Ltd. (Name of Issuer) Shares, nominal value CHF .01 per share (represented by American Depositary Shares) (Title of Class of Securities) 00654J107 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, S
November 23, 2022	SC 13D/A	CH:ADXN / Addex Therapeutics Ltd / Dyer Timothy Mark - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Addex Therapeutics Ltd (Name of Issuer) American Depositary Shares, each representing 6 ordinary shares Ordinary shares (Title of Class of Securities) 00654J107** (CUSIP Number) Timothy Mark Dyer c/o Addex Therapeutics Ltd Chemin des Mines 9, CH- 1202 Ge
November 22, 2022	424B3	Up to 1,538,462 American Depositary Shares Representing 9,230,772 Shares TABLE OF CONTENTS ?Filed pursuant to Rule 424(b)(3)? ?File No. 333-262050? PROSPECTUS Up to 1,538,462 American Depositary Shares Representing 9,230,772 Shares This prospectus relates to the resale, by the selling shareholder identified in this prospectus, of up to 1,538,462 American Depositary Shares, or ADSs, consisting of warrants to purchase up to 1,538,462 ADSs (representing 9,230,772 shares),
November 16, 2022	424B3	Up to 3,228,000 American Depositary Shares Representing 19,368,000 Shares TABLE OF CONTENTS ?Filed pursuant to Rule 424(b)(3)? ?File No. 333-266995? PROSPECTUS Up to 3,228,000 American Depositary Shares Representing 19,368,000 Shares This prospectus relates to the resale, by the selling shareholder identified in this prospectus, of up to 3,228,000 American Depositary Shares, or ADSs, consisting of (i) warrants to purchase up to 2,500,000 ADSs (representing 15,000,000 sh
November 14, 2022	EX-99.1	ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month and the nine-month periods ended
November 14, 2022	EX-99.2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators. Allosteric modulators target a specific receptor or protein and alter the effect of the body?s o
November 14, 2022	EX-99.3	Addex Reports Q3 2022 Financial Results and Provides Corporate Update EX-99.3 4 tm2230185d1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 Addex Reports Q3 2022 Financial Results and Provides Corporate Update · CHF10.4M ($10.5M) of cash and cash equivalents at September 30, 2022 · Janssen led ADX71149 Phase 2 study in epilepsy on track to complete part 1 in Q1 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2022 - Addex Therapeutics (SIX and N
November 14, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 2022 Commission File Number: 001-39179 Addex Therap UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 2022 Commission File Number: 001-39179 Addex Therapeutics Ltd (Exact Name of Registrant as Specified in Its Charter) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive offi
November 9, 2022	SC 13D/A	CH:ADXN / Addex Therapeutics Ltd / Dyer Timothy Mark - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Addex Therapeutics Ltd (Name of Issuer) American Depositary Shares, each representing 6 ordinary shares Ordinary shares (Title of Class of Securities) 00654J107** (CUSIP Number) Timothy Mark Dyer c/o Addex Therapeutics Ltd Chemin des Mines 9, CH- 1202 Ge
November 3, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal exec
November 3, 2022	EX-99.1	Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency EXHIBIT 99.1 Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 3, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (the Company), announced today that it had received written notificatio
November 1, 2022	EX-99.1	Addex Increases Issued Share Capital to Create Treasury Shares EXHIBIT 99.1 Addex Increases Issued Share Capital to Create Treasury Shares Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 1, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (the Company), announced today that it has issued 32,636,476 new registered shares
November 1, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal exec
September 14, 2022	6-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: September 2022 Commission ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: September 2022 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant?s name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Add
September 14, 2022	EX-99.1	Unaudited Interim Condensed Consolidated Financial Statements as of and for the six months ended June 30, 2022 Table of Contents Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ? Unaudited Interim Condensed Consolidated Financial Statements ? Unaudited Interim Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month and the six-mon
August 30, 2022	424B3	Up to 4,250,000 American Depositary Shares Representing 25,500,000 Shares 424B3 1 tm2223490-6424b3.htm 424B3 TABLE OF CONTENTS Filed pursuant to Rule 424(b)(3) File No. 333-266995 PROSPECTUS Up to 4,250,000 American Depositary Shares Representing 25,500,000 Shares This prospectus relates to the resale, by the selling shareholder identified in this prospectus, of up to 4,250,000 American Depositary Shares, or ADSs, consisting of (i) warrants to purchase up to 2,500,000
August 25, 2022	CORRESP	Addex Therapeutics Ltd Chemin des Mines 9, CH-1202 Geneva, Switzerland Addex Therapeutics Ltd Chemin des Mines 9, CH-1202 Geneva, Switzerland August 25, 2022 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
August 24, 2022	POS AM	As filed with the Securities and Exchange Commission on August 24, 2022. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 24, 2022.
August 24, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 4 tm2223490d2ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Post-Effective Amendment No. 2 to Form F-1 (Form Type) Addex Therapeutics Ltd. (Exact Name of Registrant as Specified in Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum O
August 23, 2022	SC 13D/A	CH:ADXN / Addex Therapeutics Ltd / Growth Equity Opportunities Fund IV, LLC - GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D/A2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Addex Therapeutics Ltd. (Name of Issuer) Shares, nominal value CHF .01 per share (represented by American Depositary Shares) (Title of Class of Securities) 00654J107 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, S
August 19, 2022	F-1	As filed with the Securities and Exchange Commission on August 19, 2022. F-1 1 tm2223490-3f1.htm F-1 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 19, 2022. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Addex Therapeutics Ltd (Exact name of registrant as specified in its charter) Switzerland (State or other
August 19, 2022	EX-10.7	Amendment to Sale Agency Agreement between Addex Therapeutics Ltd and Kepler Cheuvreux, dated June 21, 2022 Exhibit 10.7 SALE AGENCY AGREEMENT Between ADDEX THERAPEUTICS And Kepler CHEUVREUX Kepler Cheuvreux Si?ge social : 112 avenue Kl?ber 75116 Paris France http://www.keplercheuvreux.com/ T?l : +33 1 53 65 35 00 Soci?t? anonyme ? Directoire et Conseil de surveillance au capital de 56.371.350 ? RCS Paris B 413 064 841, APE 652 E Identification TVA FR 38413064841 Entreprise d?investissement r?gie par la
August 19, 2022	EX-3.1	Articles of Association of Addex Therapeutics Ltd Exhibit 3.1 Articles of Association of Addex Therapeutics Ltd I. Corporate Name, Registered Office, Duration, Purpose Article 1 Corporate Name, Registered Office, Duration Under the name Addex Therapeutics Ltd (Addex Therapeutics SA) (the "Company") exists a corporation which is subject to these Articles of Association and the provisions of Chapter 26 of the Swiss Code of Obligations (CO). The reg
August 19, 2022	EX-10.3	Amendment No. 3 to License Agreement between Indivior UK Limited and the Registrant, dated July 29, 2022 EX-10.3 4 tm2223490d4ex10-3.htm EXHIBIT 10.3   Exhibit 10.3    AMENDMENT No. 3   Whereas, Addex Pharma SA (“Addex”) and Indivior UK Limited (Co. No. 7183451) (“Indivior”) (each a “Party” and collectively the “Parties”) entered into an agreement to perform research on GABA B PAM on January 2, 2018 (hereinafter, Agreement), an amendment dated October 30, 2020 (“Amendment 1”), and an amendment with a
August 19, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 8 tm2223490d4ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) Addex Therapeutics Ltd. (Exact Name of Registrant as Specified in Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Agg
August 18, 2022	EX-99.2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators. Allosteric modulators target a specific receptor or protein and alter the effect of the body’s o
August 18, 2022	6-K	Our Report on Form 6-K, dated August 18, 2022, regarding our interim results for the six-month period ended June 30, 2022, including exhibits 99.1 and 99.2 thereto; and UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2022 Commission File Number: 001-39179 Addex Therapeutics Ltd (Exact Name of Registrant as Specified in Its Charter) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive office
August 18, 2022	EX-99.1	ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month and the six-month periods ended June
August 18, 2022	EX-99.3	Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update Exhibit 99.3 Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update ? CHF8.8M ($9.3M) of cash and cash equivalents at June 30, 2022 ? CHF4.6M equity financing in July extends cash runway into Q2 2023. ? Janssen led ADX71149 Phase 2 study in epilepsy expected to report data in Q1 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 18,
August 15, 2022	EX-99.1	Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders EXHIBIT 99.1 Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders Addex to Receive CHF850,000 ($900,000) of Additional Funding; Addex?s Reserved Indications Expanded to include Chronic Cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmac
August 15, 2022	6-K	Our Report on Form 6-K, dated August 15, 2022, and exhibit 99.1 thereto; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal execut
August 5, 2022	SC 13D/A	CH:ADXN / Addex Therapeutics Ltd / Dyer Timothy Mark - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Addex Therapeutics Ltd (Name of Issuer) American Depositary Shares, each representing 6 ordinary shares Ordinary shares (Title of Class of Securities) 00654J107** (CUSIP Number) Timothy Mark Dyer c/o Addex Therapeutics Ltd Chemin des Mines 9, CH- 1202 Ge
July 26, 2022	6-K	The disclosure in our Report on Form 6-K, dated July 26, 2022, under the heading “Registered Direct Offering and Concurrent Private offering” and exhibits 4.1, 4.2, 5.1, 10.1, 10.2, and 99.1 thereto; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of July 2022 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant?s name into English) Chemin des Mines 9 CH-1202 Geneva, Switzerland (Address of principal executive
July 26, 2022	EX-99.1	Addex Completes $4.2 Million Equity Financing EX-99.1 7 tm2221626d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Addex Completes $4.2 Million Equity Financing Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 26, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has completed an equity fina
July 26, 2022	EX-10.2	Amendment No. 1 to Securities Purchase Agreement, dated July 22, 2022 between the Registrant and Armistice Capital Master Fund Ltd. (incorporated by reference to Exhibit 10.2 of Form 6-K filed on July 26, 2022) Exhibit 10.2 AMENDMENT NO .1 TO SECURITIES PURCHASE AGREEMENT This AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT (this ?Amendment?) is entered into effective July 22, 2022 by and between Addex Therapeutics Ltd. a soci?t? anonyme organized under the laws of Switzerland (the ?Company?) and Armistice Capital Master Fund Ltd. (?Purchaser?). Capitalized terms used but not defined herein have the mea
July 26, 2022	EX-4.2	Form of July 2022 Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 of Form 6-K filed on July 26, 2022) Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
July 26, 2022	EX-4.1	exhibits 4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
July 26, 2022	EX-10.1	Securities Purchase Agreement, dated July 22, 2022 between the Registrant and Armistice Capital Master Fund Ltd. (incorporated by reference to Exhibit 10.1 of Form 6-K filed on July 26, 2022) Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 22, 2022, between Addex Therapeutics Ltd, a soci?t? anonyme organized under the laws of Switzerland (the ?Company?), and the purchaser identified on the signature pages hereto (the ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to
July 26, 2022	424B5	4,500,000 Shares (in the form of 750,000 American Depositary Shares) CHF 0.27 per Share $1.70 per American Depositary Share TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-255089 PROSPECTUS SUPPLEMENT (to Prospectus dated April 13, 2021) 4,500,000 Shares (in the form of 750,000 American Depositary Shares) CHF 0.27 per Share $1.70 per American Depositary Share We are offering 4,500,000 shares in the form of American Depositary Shares, or ADSs, in the United States to an institutional
July 22, 2022	6-K	Our Report on Form 6-K, dated July 22, 2022, and exhibit 99.1 thereto; 6-K 1 f6k072222.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (
July 22, 2022	EX-99.1	Addex Raises $4.2 million in Equity Financing EXHIBIT 99.1 Addex Raises $4.2 million in Equity Financing Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 ? Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with Armistice Master Fund LTV, a
July 21, 2022	6-K	Our additional Report on Form 6-K, dated July 21, 2022, and exhibit 99.1 thereto; 6-K 1 f6k072122.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (
July 21, 2022	EX-99.1	Addex Completes Reduction in Nominal Value of Shares EXHIBIT 99.1 Addex Completes Reduction in Nominal Value of Shares Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 21, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the reduction of the nominal value of its issued, authorized and conditional
July 21, 2022	EX-99.1	Addex Provides Corporate Update and Financial Guidance EXHIBIT 99.1 Addex Provides Corporate Update and Financial Guidance Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 21, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today provided a corporate update, including a review of its pipeline and financial guidanc
July 21, 2022	6-K	Our Report on Form 6-K, dated July 21, 2022, and exhibit 99.1 thereto; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executiv
July 20, 2022	424B5	Up to 2,451,557 American Depositary Shares Representing 14,709,342 Shares TABLE OF CONTENTS ?Filed pursuant to Rule 424(b)(5) ?File No. 333-262050? PROSPECTUS Up to 2,451,557 American Depositary Shares Representing 14,709,342 Shares This prospectus relates to the resale, by the selling shareholder identified in this prospectus, of up to 2,451,557 American Depositary Shares, or ADSs, consisting of (i) warrants to purchase up to 1,538,462 ADSs (representing 9,230,772 shar
June 17, 2022	EX-99.1	Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate EXHIBIT 99.1 Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson?s Disease due to Slow Recruitment Rate COVID-19 related challenges negatively impacted patient recruitment Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 17, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneerin
June 17, 2022	6-K	Our report on Form 6-K, dated June 17, 2022, and exhibit 99.1 thereto; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executiv
May 27, 2022	6-K	Our report on Form 6-K, dated May 27, 2022, and exhibit 99.1 thereto; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive
May 27, 2022	EX-99.1	Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study EXHIBIT 99.1 Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 27, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the outcome of a small Phase 2a feasibi
May 10, 2022	6-K	Our report on Form 6-K, dated May 10, 2022, and exhibit 99.1 thereto; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive
May 10, 2022	EX-99.1	Addex Shareholders Approve All Resolutions at Annual General Meeting EXHIBIT 99.1 Addex Shareholders Approve All Resolutions at Annual General Meeting Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2022 ? Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all of the proposals of t
May 5, 2022	EX-99.1	ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month periods ended March 31, 2022 and 202
May 5, 2022	6-K	Our report on Form 6-K, dated May 5, 2022, regarding our interim results for the three-month period ended March 31, 2022, including exhibits 99.1 and 99.2 thereto; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2022 Commission File Number: 001-39179 Addex Therapeutics Ltd (Exact Name of Registrant as Specified in Its Charter) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executive offices)
May 5, 2022	EX-99.2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators. Allosteric modulators target a specific receptor or protein and alter the effect of the body?s o
May 5, 2022	EX-99.3	Addex Reports Q1 2022 Financial Results EX-99.3 4 tm2214454d1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 Addex Reports Q1 2022 Financial Results · CHF14.9M ($16.1M) of cash and cash equivalents at March 31, 2022 · Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022 · Phase 2b/3 dipraglurant study in dyskinesia associated with Parkinson’s disease expected to report data in H1 2023 · Janssen led ADX71149 Phase 2
April 13, 2022	6-K	Our report on Form 6-K, dated April 13, 2022, and exhibit 99.1 thereto; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland (Address of principal executi
April 13, 2022	EX-99.1	Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study Top-line Data Scheduled to Report in Q2 2022 EX-99.1 2 exh991.htm EXHIBIT 99.1 EXHIBIT 99.1 Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study Top-line Data Scheduled to Report in Q2 2022 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-ba
April 6, 2022	EX-99.1	Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders New Series of Potent and Selective Compounds Identified Using Proprietary Allosteric Modulator Screening Pla EX-99.1 2 exh991.htm EXHIBIT 99.1 EXHIBIT 99.1 Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders New Series of Potent and Selective Compounds Identified Using Proprietary Allosteric Modulator Screening Platform Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 6, 2022 - Addex Therapeutic
April 6, 2022	6-K	Our report on Form 6-K, dated April 6, 2022, and exhibit 99.1 thereto; 6-K 1 f6k040622.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-39179 Addex Therapeutics Ltd (Translation of registrant's name into English) Chemin des Mines 9, CH-1202 Geneva, Switzerland

ADXN / Addex Therapeutics Ltd - Depositary Receipt (Common Stock) - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings